Ratios Revealed: Decoding Alx Oncology Holdings Inc (ALXO)’s Financial Health

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The closing price of Alx Oncology Holdings Inc (NASDAQ: ALXO) was $8.67 for the day, down -3.77% from the previous closing price of $9.01. In other words, the price has decreased by -$3.77 from its previous closing price. On the day, 0.55 million shares were traded. ALXO stock price reached its highest trading level at $8.97 during the session, while it also had its lowest trading level at $8.55.


Our analysis of ALXO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.21. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on March 08, 2024, Downgraded its rating to Hold and sets its target price to $14 from $10 previously.

On December 08, 2023, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $8 to $18.

Jefferies Downgraded its Buy to Hold on December 22, 2021, whereas the target price for the stock was revised from $65 to $25.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 04 ’24 when Pons Jaume sold 20,000 shares for $8.43 per share. The transaction valued at 168,652 led to the insider holds 604,205 shares of the business.

Randolph Sophia sold 12,000 shares of ALXO for $191,339 on May 13 ’24. The CHIEF MEDICAL OFFICER now owns 330,349 shares after completing the transaction at $15.94 per share. On May 06 ’24, another insider, Pons Jaume, who serves as the PRESIDENT & CSO of the company, sold 20,000 shares for $15.92 each. As a result, the insider received 318,334 and left with 604,205 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 451707872 and an Enterprise Value of 311112928.

Stock Price History:

Over the past 52 weeks, ALXO has reached a high of $17.83, while it has fallen to a 52-week low of $3.94. The 50-Day Moving Average of the stock is -36.71%, while the 200-Day Moving Average is calculated to be -23.19%.

Shares Statistics:

ALXO traded an average of 681.37K shares per day over the past three months and 1280550 shares per day over the past ten days. A total of 49.95M shares are outstanding, with a floating share count of 29.07M. Insiders hold about 44.20% of the company’s shares, while institutions hold 56.45% stake in the company. Shares short for ALXO as of 1715731200 were 3360410 with a Short Ratio of 4.93, compared to 1713139200 on 3694845. Therefore, it implies a Short% of Shares Outstanding of 3360410 and a Short% of Float of 11.2799995.

Earnings Estimates

The dynamic stock of Alx Oncology Holdings Inc (ALXO) is currently attracting attention from 6.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.76 for the current quarter, with a high estimate of -$0.69 and a low estimate of -$0.84, while EPS last year was -$0.84. The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.59 and low estimates of -$0.82.

Analysts are recommending an EPS of between -$2.56 and -$3.16 for the fiscal current year, implying an average EPS of -$2.89. EPS for the following year is -$2.84, with 5.0 analysts recommending between -$2.13 and -$3.34.

Most Popular